Moreover, the underuse of older, less expensive AOMs has permitted skyrocketing prescribing of new, expensive incretin mimetics for weight management (‘Obesity and GLP-1 Drugs’ 2025), which may not be necessary for or preferred by individual patients (Do et al. 2024). The gene discussed is GCG; the disease is obesity disorder.